{"publication_id":"e7c852f1-873a-4cb5-98d6-2f49fad6de83","screening":{"identified":53,"screened":53,"excluded":0,"included":53,"included_or_retained":53,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"53 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The corpus contains 3 direct clinical sources, 49 adjacent clinical sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.","The thesis is: Across 53 curated reference papers, the evidence base for Statins shows a context-dependent profile. Positive signals appear in: contextual other, longevity. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Statins anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.","Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.","The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","Mechanistically, the cardiometabolic class triangulates three distinct causal substrates. In a clinical observational cohort, Alqasrawi 2025 frames statin tolerability as a pharmacogenomic problem, with adverse-event incidence modulated by SLCO1B1- and CYP3A4-related variants (Alqasrawi 2025). Mechanistic human data from Spiegeleer 2025 implicate concomitant-medication burden, suggesting that gait-speed decrements in statin users may reflect polypharmacy rather than statin monotherapy (Spiegeleer 2025). Preclinical and clinical lipid-pathway evidence in Masood 2026 positions PPAR-α agonism as an alternative triglyceride-lowering route, indirectly testing whether the cardiometabolic benefits traditionally attributed to statins can be recapitulated by a mechanistically adjacent agent (Masood 2026). Together, these substrates frame cardiometabolic change as a function of lipid handling, drug clearance genetics, and concomitant exposures rather than a single longevity pathway.","Within-corpus tensions surface chiefly through disagreement over whether statin exposure is harmful, neutral, or beneficial on cardiometabolic surrogates. Alqasrawi 2025 reports mixed adverse-event signals with effect direction marked unclear and individual p-values spanning P = 0.0730 to P < 0.0001, indicating that some adverse outcomes track robustly with statin exposure while others do not (Alqasrawi 2025). The integrating thesis that Statins presents a context-dependent profile is consistent with these source-level disagreements: positive, null, and adverse signals coexist across the cardiometabolic class, and no single source resolves the direction of effect on longevity-relevant cardiometabolic endpoints."]}